The 8 analysts offering 12-month price forecasts for Royalty Pharma PLC have a median target of 51.50, with a high estimate of 56.00 and a low estimate of 50.00. The median estimate represents a +19.52% increase from the last price of 43.09.
The current consensus among 9 polled investment analysts is to Hold stock in Royalty Pharma PLC. This rating has held steady since April, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.71
Reporting Date Aug 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.